{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:41:43Z","timestamp":1768995703780,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contraceptionjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.contraception.2016.03.010","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T09:29:05Z","timestamp":1458293345000},"page":"104-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["The elusive minimum threshold concentration of levonorgestrel for contraceptive efficacy"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-0443","authenticated-orcid":false,"given":"Ganesh","family":"Cherala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laneta","family":"Dorflinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank Z.","family":"Stanczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2016.03.010_bb0005","author":"Ellertson"},{"issue":"2","key":"10.1016\/j.contraception.2016.03.010_bb0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/07853899309164160","article-title":"NORPLANT: levonorgestrel-releasing contraceptive implant","volume":"25","author":"Croxatto","year":"1993","journal-title":"Ann Med"},{"key":"10.1016\/j.contraception.2016.03.010_bb0015","series-title":"Long-acting contraceptives","author":"Primiero","year":"1994"},{"key":"10.1016\/j.contraception.2016.03.010_bb0020","series-title":"Norplant: the first implantable contraceptive","author":"Bardin","year":"1992"},{"issue":"5","key":"10.1016\/j.contraception.2016.03.010_bb0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0010-7824(83)90045-8","article-title":"Release rates of levonorgestrel from silastic capsules, homogeneous rods and covered rods in humans","volume":"27","author":"Robertson","year":"1983","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.contraception.2016.03.010_bb0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0010-7824(87)90024-2","article-title":"Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANT implants or two covered rods (NORPLANT-2)","volume":"35","author":"Olsson","year":"1987","journal-title":"Contraception"},{"issue":"8","key":"10.1016\/j.contraception.2016.03.010_bb0035","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/clinchem\/35.8.1722","article-title":"Variations in protein binding of drugs in plasma and serum","volume":"35","author":"Ohshima","year":"1989","journal-title":"Clin Chem"},{"key":"10.1016\/j.contraception.2016.03.010_bb0040","author":"El-Migdadi"},{"issue":"2","key":"10.1016\/j.contraception.2016.03.010_bb0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0010-7824(81)90105-0","article-title":"Plasma levels of levonorgestrel in women during long-term use of Norplant","volume":"23","author":"Croxatto","year":"1981","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2016.03.010_bb0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0010-7824(90)90093-B","article-title":"Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids","volume":"42","author":"Stanczyk","year":"1990","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.contraception.2016.03.010_bb0055","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0010-7824(75)90088-8","article-title":"Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration","volume":"12","author":"Stanczyk","year":"1975","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.contraception.2016.03.010_bb0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0010-7824(75)90087-6","article-title":"Peripheral plasma levels of d-norgestrel in women after oral administration of d-norgestrel and when using intravaginal rings impregnated with dl-norgestrel","volume":"12","author":"Victor","year":"1975","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.03.010_bb0065","series-title":"Fertility control club hormonal contraception methods: from basic research to clinical practice","article-title":"Measuring total plasma levonorgestrel (LNG) levels among users of contraceptive implants: a comparison of radioimmunoassay and mass spectrometry methods","year":"2015"},{"issue":"10","key":"10.1016\/j.contraception.2016.03.010_bb0070","first-page":"855","article-title":"Traditional assay methodology, drug species, and perinatal growth: a perfect storm for oral contraceptive failure among obese women","volume":"23","author":"Cherala","year":"2014","journal-title":"J Womens Health"},{"issue":"3\u20135","key":"10.1016\/j.contraception.2016.03.010_bb0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jsbmb.2010.05.001","article-title":"Advantages and challenges of mass spectrometry assays for steroid hormones","volume":"121","author":"Stanczyk","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"12","key":"10.1016\/j.contraception.2016.03.010_bb0080","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.contraception.2016.03.010_bb0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1185\/1463009001527660","article-title":"Introduction to clinical pharmacokinetics","volume":"4","author":"Thomson","year":"2000","journal-title":"Paediatr Perinat Drug Ther"},{"issue":"7","key":"10.1016\/j.contraception.2016.03.010_bb0090","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.tips.2005.05.007","article-title":"Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance","volume":"26","author":"Buccafusco","year":"2005","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.contraception.2016.03.010_bb0095","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.contraception.2010.01.016","article-title":"Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women","volume":"81","author":"Westhoff","year":"2010","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.contraception.2016.03.010_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.contraception.2009.04.011","article-title":"Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic\u2013pituitary\u2013ovarian activity","volume":"80","author":"Edelman","year":"2009","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.contraception.2016.03.010_bb0105","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.contraception.2012.10.008","article-title":"Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users","volume":"87","author":"Edelman","year":"2013","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.contraception.2016.03.010_bb0110","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.contraception.2014.06.033","article-title":"Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial","volume":"90","author":"Edelman","year":"2014","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2016.03.010_bb0115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.contraception.2008.02.020","article-title":"Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins","volume":"78","author":"Goldzieher","year":"2008","journal-title":"Contraception"},{"issue":"1\u20132","key":"10.1016\/j.contraception.2016.03.010_bb0120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jsbmb.2004.02.003","article-title":"Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins","volume":"91","author":"Garcia-Becerra","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"10.1016\/j.contraception.2016.03.010_bb0125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MED.0b013e328353732f","article-title":"Evolving utility of sex hormone-binding globulin measurements in clinical medicine","volume":"19","author":"Hammond","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"10.1016\/j.contraception.2016.03.010_bb0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mce.2009.08.025","article-title":"Genetic variants of sex hormone-binding globulin and their biological consequences","volume":"316","author":"Xita","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1016\/j.contraception.2016.03.010_bb0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2009.09.020","article-title":"Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome","volume":"316","author":"Pugeat","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"10.1016\/j.contraception.2016.03.010_bb0140","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1210\/jc.2009-0713","article-title":"Familial correlations in postmenopausal serum concentrations of sex steroid hormones and other mitogens: a twins and sisters study","volume":"94","author":"Stone","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.contraception.2016.03.010_bb0145","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF02042590","article-title":"Free levonorgestrel index and its relationship with luteal activity during long-term use of Norplant implants","volume":"8","author":"Brache","year":"1992","journal-title":"Adv Contracept"},{"issue":"10 Pt 1","key":"10.1016\/j.contraception.2016.03.010_bb0150","first-page":"1065","article-title":"Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations","volume":"11","author":"Rinaldi","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.contraception.2016.03.010_bb0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.beem.2006.03.007","article-title":"Diagnosis of hyperandrogenism: biochemical criteria","volume":"20","author":"Stanczyk","year":"2006","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.contraception.2016.03.010_bb0160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4155\/bio.13.338","article-title":"Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European Bioanalysis Forum","volume":"6","author":"Buscher","year":"2014","journal-title":"Bioanalysis"},{"issue":"2","key":"10.1016\/j.contraception.2016.03.010_bb0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/ecp.13.6","article-title":"Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives","volume":"6","author":"Trivedi","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.contraception.2016.03.010_bb0170","doi-asserted-by":"crossref","first-page":"E390","DOI":"10.1208\/aapsj070240","article-title":"Modeling and simulation of adherence: approaches and applications in therapeutics","volume":"7","author":"Kenna","year":"2005","journal-title":"AAPS J"},{"issue":"8","key":"10.1016\/j.contraception.2016.03.010_bb0175","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/jac\/dks164","article-title":"Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine","volume":"67","author":"Dorlo","year":"2012","journal-title":"J Antimicrob Chemother"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782416001025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782416001025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T09:04:19Z","timestamp":1600333459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782416001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0010782416001025"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2016.03.010","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The elusive minimum threshold concentration of levonorgestrel for contraceptive efficacy","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2016.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}